Elekta AB (OTCMKTS:EKTAY) Sees Significant Drop in Short Interest

Elekta AB (OTCMKTS:EKTAY) was the target of a significant drop in short interest in the month of August. As of August 14th, there was short interest totaling 6,134 shares, a drop of 62.4% from the July 30th total of 16,311 shares. Based on an average daily volume of 5,460 shares, the short-interest ratio is presently 1.1 days. Currently, 0.0% of the company’s shares are short sold.

Wall Street Analyst Weigh In

Separately, Zacks Research raised shares of Elekta from a “strong sell” rating to a “hold” rating in a research note on Tuesday, July 28th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Elekta presently has a consensus rating of “Reduce”.

Elekta Stock Down 3.3%

Elekta stock opened at $5.50 on Friday. The company has a quick ratio of 0.68, a current ratio of 0.87 and a debt-to-equity ratio of 0.47. The firm has a market cap of $2.03 billion, a P/E ratio of -34.38 and a beta of 1.01. The business has a fifty day moving average of $5.19 and a two-hundred day moving average of $5.70. Elekta has a twelve month low of $4.35 and a twelve month high of $6.93.

Elekta (OTCMKTS:EKTAY) last released its quarterly earnings results on Thursday, August 27th. The company reported $0.07 EPS for the quarter. The firm had revenue of $372.30 million during the quarter. Elekta had a positive return on equity of 11.11% and a negative net margin of 3.32%. On average, analysts forecast that Elekta will post 0.43 earnings per share for the current fiscal year.

Elekta Company Profile

Elekta is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment.